Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding
Others
Ratios

NewAmsterdam Pharma (NAMSW) Other Non Operating Income (2023 - 2025)

Historic Other Non Operating Income for NewAmsterdam Pharma (NAMSW) over the last 3 years, with Q3 2025 value amounting to $23.8 million.

  • NewAmsterdam Pharma's Other Non Operating Income rose 40815.89% to $23.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $38.2 million, marking a year-over-year decrease of 72.96%. This contributed to the annual value of $38.6 million for FY2024, which is 28513.68% up from last year.
  • As of Q3 2025, NewAmsterdam Pharma's Other Non Operating Income stood at $23.8 million, which was up 40815.89% from $8.6 million recorded in Q2 2025.
  • NewAmsterdam Pharma's Other Non Operating Income's 5-year high stood at $30.2 million during Q1 2024, with a 5-year trough of -$13.8 million in Q1 2025.
  • Moreover, its 3-year median value for Other Non Operating Income was $4.7 million (2024), whereas its average is $7.0 million.
  • Data for NewAmsterdam Pharma's Other Non Operating Income shows a peak YoY increase of 88624.06% (in 2024) and a maximum YoY decrease of 906111.11% (in 2024) over the last 5 years.
  • Quarter analysis of 3 years shows NewAmsterdam Pharma's Other Non Operating Income stood at $10.2 million in 2023, then surged by 92.33% to $19.6 million in 2024, then rose by 21.54% to $23.8 million in 2025.
  • Its last three reported values are $23.8 million in Q3 2025, $8.6 million for Q2 2025, and -$13.8 million during Q1 2025.